City of Hope launches first CAR T cell trial targeting CS1 protein in multiple myeloma

April 26, 2019 | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.

Continue Reading

City of Hope investigates a novel therapeutic approach in AML

April 26, 2019 | City of Hope

City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.

City of Hope launches first CAR T cell trial targeting CS1 protein in multiple myeloma

April 26, 2019 | City of Hope

City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.

City of hope innovating how to decrease cmv infections in transplants via novel vaccine approach

February 26, 2019 | City of Hope

Cytomegalovirus (CMV) can cause severe and life-threatening disease in patients undergoing a stem cell or solid organ transplant. City of Hope researchers have been developing a novel vaccine against CMV to decrease the risk of infections in this procedure.

The Changing Landscape of Lung Cancer Therapy

November 27, 2018 | City of Hope

City of Hope clinical trials reflect the rapidly changing landscape of lung cancer therapy. We continue to pioneer treatment in lung cancer with trials that incorporate biomarker testing and immunotherapy.

First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases

October 30, 2018 | City of Hope

City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.

City of Hope posts higher breast cancer survival rates at all stages

October 9, 2018 | City of Hope

City of Hope is proud of having higher survival rates at all stages of breast cancer than those of the Los Angeles Registry of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.

New hormone and immunotherapy trial for breast cancer patients

October 8, 2018 | City of Hope

This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.

Patients over 60 needed for HER2-positive breast cancer study

October 7, 2018 | City of Hope

Researchers are actively recruiting for patients 60 years and older for a phase 2 trial studying the side effects of and how well neratinib works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to other places in the body.

New CAR T Cell Therapy Breakthroughs Announced at ASH

December 14, 2017 | Letisia Marquez

New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.